



Title	The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats
Author(s)	Zhan, H; Sun, SJ; Cai, J; Li, YQ; Hu, CL; Lee, DHS; So, KF; Li, X
Citation	Neurochemical Research, 2013, v. 38 n. 7, p. 1333-1340
Issued Date	2013
URL	http://hdl.handle.net/10722/184457
Rights	The original publication is available at www.springerlink.com

Neurochemical Research

The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats --Manuscript Draft--

Manuscript Number:	NERE2930R2
Full Title:	The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats
Article Type:	Original
Keywords:	Nogo-66 receptor; Axon; Cortical infarction; regeneration; Signal pathway
Corresponding Author:	Xin Li CHINA
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	
Corresponding Author's Secondary Institution:	
First Author:	Hong Zhan
First Author Secondary Information:	
Order of Authors:	Hong Zhan Shu-Jie Sun Jie Cai Ying-Qing Li Chun-Lin Hu Daniel H.S. Lee Kwok-Fai So Xin Li
Order of Authors Secondary Information:	

The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats

Running title: The neuroprotection of NgR1 antagonist on cortical axons

Hong Zhan^{1,6}, Shu-Jie Sun^{4,6}, Jie Cai¹, Ying-Qing Li¹, Chun-Lin Hu¹, Daniel H.S. Lee³, Kwok-Fai So^{2,5}, Xin Li¹

¹Department of Emergency, The First Affiliated Hospital, Sun Yat-sen University, 58 ZhongShan II, Guangzhou, Guangdong, 510080, China

²Department of Anatomy and The State Key Laboratory of Brain and Cognitive sciences, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China

³Roche R&D Center (China) Ltd. 720 Cai Lun Road, Building, Pudong, Shanghai 201203, China

⁴Emergency Department, East Hospital of TongJi University, 150 Jimo Road, Shanghai, People's Republic of China

⁵GHM Institute of CNS Regeneration, Jinan University, Guangzhou, China

⁶These authors contributed equally to this work.

Correspondence to:

Xin Li, MD

Associate Professor

Department of Emergency

The First Affiliated Hospital

Sun Yat-sen University

58 ZhongShan Road II, Guangzhou, Guangdong, 510080, China

Telephone: +86-20-28823350

Fax: +86-20-28823350.

E-mail: xlidoct@qq.com

Abstract

1 We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of
2 cortical axons after cortical infarction in rats. The cortical infarction was induced by
3
4 photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was
5
6 injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

serious pathologies were found in the brains of the rats after injury, including edemas in the axoplasms of axons that have no medulla sheath and a thickening or shrinkage in the sheath of the axons that have medulla sheathes. However, these pathologies improved after sNgR-Fc treatment. The levels of GTP-RhoA, p-JNK, p-c-JUN and p-ATF-2 in the PCI group were increased when compared with their levels in the sham-operation group ($P < 0.05$), and animals receiving the sNgR-Fc treatment showed lower expression levels of these proteins when compared with the sham-operation group ($P < 0.05$). Our results suggest that sNgR-Fc can alleviate the pathological changes of axons following cortical infarction via decreasing the activation of RhoA/JNK signaling pathways.

Key words: Nogo-66 receptor; Axon; Cortical infarction; Regeneration; Signal pathway

Introduction

1 A brain infarction (also known as an ischemic stroke) is caused by the blockage of a cerebral
2 artery by a blood clot, which results in the following effects: a critical reduction in blood flow,
3
4 ischemia, anoxia, and, finally, ischemic necrosis or encephalomalacia in the brain. This
5
6 condition is characterized clinically by high morbidity, high mortality, high disability rate,
7
8 high recurrence rates, and it is difficult to treat. Because our population is aging, stroke is
9
10 becoming a more serious threat and an urgent medical problem. Previous studies have shown
11
12 that the central nerve system cannot regenerate after injury, as a result of factors that include
13
14 the insufficiency of neural progenitor cells (NPCs) and a microenvironment that inhibits the
15
16 regeneration of neurons [1]. Recent studies have demonstrated that the inhibition of axon
17
18 regeneration after injuries to the central nervous system (CNS) were associated with several
19
20 CNS myelin proteins, including Nogo-A, myelin-associated glycoprotein (MAG), and
21
22 oligodendrocyte myelin glycoprotein (OMgp). These three proteins bind to the Nogo-66
23
24 receptor (NgR1), which then leads to the downstream activation of RhoA (Ras homolog gene
25
26 family, member A) via two transmembrane proteins, LINGO-1 and p75; these proteins inhibit
27
28 the activity in neurons and their axons [2–4]. Jun N-terminal kinases (JNKs) are intracellular
29
30 molecules related to stress stimuli. The activation of these molecules mediates many types of
31
32 injury-induced apoptosis and plays a role in the regeneration of axons. However, the role of
33
34 the JNK-signaling pathway in the presence of a brain infarction is still unclear. The
35
36 administration of sNgR-Fc, a recombinant rat soluble NgR-Fc fusion protein [5], has been
37
38 found to block the interaction of myelin proteins with NgR1 effectively and to promote the
39
40 regeneration of axons in rodent models of CNS injuries such as spinal cord injury [6–10]. A
41
42 previous study has shown that anti-Nogo-A antibody promoted the behavioral outcome and
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 corticospinal plasticity in a rat stroke model [11]. In this study, we established a stroke model
2 in rats and observed the effects of sNgR-Fc on the axonal pathology and the involved
3
4 RhoA/JNK signaling pathways after cortical infarction.
5
6
7
8
9

10 **Experimental Procedure**

11 **Animals**

12
13 The animal experiments were approved by the Committee for the Use of Live Animals in
14
15 Teaching and Research at the Sun Yat-sen University. All of the experiments were performed
16
17
18 in a fully randomized and blinded fashion.
19
20
21
22

23 **Photothrombotic cortical injury**

24
25 Photothrombotic ischemia was induced in the rat parietal cortex using previously described
26
27 methods [9,11,12] with the modifications as outlined below. Twenty seven male SD rats
28
29 weighing 250 g were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and
30
31 xylazine (8 mg/kg). Dilute Rose-Bengal in saline (40 mg/kg body weight) was infused into
32
33 the femoral vein. The portion of the skull exposed at 3 mm posteriorly to the bregma and 3
34
35 mm laterally from the midline was illuminated with a cold, white light beam (Volpi Intralux
36
37 6000, 150 W; Volpi AG, Schlieven, Switzerland) for 8 min at maximum output via a
38
39 fiber-optic bundle with a 10 mm aperture. The animals were randomly grouped into
40
41 sham-operation (operation + Rose-Bengal), PBS (operation + Rose-Bengal + PBS), or
42
43 sNgR-Fc (operation + Rose-Bengal + sNgR-Fc) groups ($n = 9$ for each group). A solution of
44
45 sNgR-Fc (400 μ g/kg body weight) in 10 μ l PBS or equivalent PBS was only once injected
46
47 into the ipsilateral ventricle using a 26-gauge sterile microsyringe 24 h after photothrombotic
48
49 cortical injury [11]. The site of injection was at 1 mm posteriorly to the bregma and 1.5 mm
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 laterally from the midline, and the depth of injection was about 3.5~4.0 mm. For each group,
2 the whole cerebrum of 3 animals was collected 24 h after injury for tissue staining. The
3
4 ipsilateral cortex of peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm
5
6
7 laterally from the midline of rats was collected at 27 d after injury for electron microscopy
8
9
10 examination ($n = 3$ for each group) and for Western blotting ($n = 3$ for each group).
11
12
13
14

15 **Triphenyltetrazolium chloride staining**

16
17
18 To evaluate the extent of cortical infarction, we used 2, 3, 5-Triphenyltetrazolium chloride
19
20
21 (TTC) to assess cerebral injury. At 24 h after PCI, the animals were sacrificed using an
22
23
24 overdose of pentobarbital sodium (150 mg/kg, Alcon-Couvreur, Rijksweg, Puurs, Belgium).
25
26
27 The brains were removed immediately and then were chilled at $-30\text{ }^{\circ}\text{C}$ for 4 min to slightly
28
29
30 freeze the tissue. Two-mm coronal sections from the olfactory bulb to the cerebellum were
31
32
33 prepared, stained with 1.5% TTC (Genetime) at $37\text{ }^{\circ}\text{C}$ for 30 min, and fixed in 10% buffered
34
35
36 formalin solution.
37

38 **Transmission electron microscopy**

39
40
41 Seven days after PCI, the peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm
42
43
44 laterally from the midline on the injury side was removed and immediately cut into 0.5 cm^3
45
46
47 cubes at $0\text{ }^{\circ}\text{C}$, fixed with 4% paraformaldehyde for 4 h, and washed with PBS. Then, the
48
49
50 tissue was fixed with 2% osmic acid for 2 h, washed with pure water, dehydrated with a
51
52
53 mixture of ethanol, propylene oxide, and resin, embedded in pure resin, and ultramicrocut
54
55
56 and stained with uranyl acetate and lead citrate [13, 14]. The sections were observed under an
57
58
59 HE-800 transmission electron microscope (Hitachi, Japan).
60

61 **Western blotting**

1
2 The cortex from the injury side was collected at 7 days after injury and homogenized in a
3
4 lysis buffer (in mM: Tris, 10, pH 7.4; NaCl, 150; EDTA, 1; EGTA, 1; 10% protease inhibitor,
5
6 1% phosphatase inhibitor), and incubated on ice for 30 min. The protein lysate was then
7
8 centrifuged at 13,500 rpm for 30 min at 4 °C. The supernatant was aliquoted and stored at
9
10 -80 °C until its use. The supernatant was measured for its protein concentration using a
11
12 Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 40 µg aliquot of protein
13
14 from each sample was subjected to 5–12% SDS–polyacrylamide gel electrophoresis and
15
16 transferred onto a PVDF membrane. Each membrane was blocked with 5% non-fat milk and
17
18 2% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h
19
20 at room temperature and then probed with rabbit anti-p-JNK (Cell Signaling Technology,
21
22 MA, USA), anti-p-c-JUN (Cell Signaling Technology), p-ATF-2 (Cell Signaling
23
24 Technology), total-JNK (Cell Signaling Technology) and total-RhoA antibodies at 4 °C
25
26 overnight. As a gel loading control, β-actin was used. After washing, the membranes were
27
28 incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:2000;
29
30 DakoCytomation, Denmark). Its immunoreactivity was visualized using the Amersham
31
32 enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA). The protein loading
33
34 was controlled using the goat antibody against β-actin (C-11; Santa Cruz Biotechnology).
35
36 The quantification of the results was performed by densitometry, and the results were
37
38 analyzed as total integrated densitometric values (arbitrary units). The protein GTP-RhoA
39
40 was pulled down using a RhoA activation assay kit, according to the manufacturer's
41
42 instruction (Cytoskeleton, Denver, CO, USA) and assayed by Western blotting using an
43
44 antibody against RhoA (Cytoskeleton). All experiments for Western blotting were performed
45
46 with 3 animals in each group, and the samples were run on the gels as individual animals.
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Data and statistical analysis

1 The values are presented as the mean \pm SD. The statistical analyses was performed
2
3
4 using Student's t-test for comparisons between two groups or the one-way analysis of
5
6 variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) for comparisons of
7
8 more than two groups. The data were analyzed statistically with the software SPSS 12.0. The
9
10 significance level was set at $P < 0.05$.
11
12
13
14
15
16
17

Results

Measurement of brain infarct volume and identification of blood brain barrier integrity

21 After TTC staining, the rats in the sham group did not appear to have any infarctions (Fig.
22
23 1b). However, the right parietal lobes of the rats 24 h after PCI presented pale infarctions that
24
25 were bowl-shaped, with the bottom pointing to the lateral ventricle; these infarctions affected
26
27 the entire cortex. The total infarct volumes were $297.1 \pm 23.4 \mu\text{l}$ in the PBS group and
28
29 $285.4 \pm 19.7 \mu\text{l}$ for the sNgR-Fc group respectively before the treatment. The locations of
30
31 the infarctions were stable, and the infarctions showed similar volumes to those in the rats
32
33 (Fig. 1).
34
35
36
37
38
39
40
41
42

Pathological changes of axons

43 The morphology of ischemic penumbra on the injury side was evaluated using TEM at 7 days
44
45 after PCI. Compared with the normal axons observed in the sham group (Fig. 2a), more
46
47 serious pathologies were observed in the PCI group (Fig. 2b). For the axons without a
48
49 medulla sheath, many edemas, dilutions of cytoplasmic matrices, and axonal fusions or
50
51 dissolutions were found. Occasionally, we observed that oligodendrocytes appeared to
52
53 “swallow” the axons (Fig. 2b). For axons with a medulla sheath, compared with the sham
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

group, thickening or shrinking was more in the axoplasm of the fibers, and amyloidosis and swollen axons were observed at a higher rate. In addition, the axolemma were found to be separated from the inner layers of the myelin (Fig. 2e). In addition, there were only minor pathological changes, including slight nuclear edemas with complete nucleoli, slightly swollen mitochondria, and slightly widened endoplasmic reticula with complete ribosomes and Golgi bodies. In unmyelinated axons, there were some axonal edemas, axonal deformities, and dilutions of cytoplasmic matrices; in addition, there were no axonal fusions or cytophagic effects of oligodendrocytes (Fig. 2c). In myelinated axons, the morphology of axons was almost normal. There was little demyelination and no amyloidosis of the myelin sheath was found (Fig. 2f). Compared with normal synapses (Fig. 2g), the synaptic cleft widened, and there was edema in the PBS group (Fig. 2h). However, no clear edema or widening of the synaptic cleft was observed in the group that received the sNgR-Fc treatment (Fig. 2i).

sNgR-Fc inhibited RhoA signal pathway

The level of GTP-RhoA in the PBS group was significantly higher than that in the sham-operation group ($P < 0.05$). After treatment with sNgR-Fc, the level of GTP-RhoA was significantly decreased. Moreover, the level of Total-RhoA was not different among the three groups (Fig.3, Table 1). These data indicate that sNgR-Fc could decrease the activation of RhoA.

sNgR-Fc inhibit the activation of SAPK/JNK signal pathway

The levels of p-JNK1, 2 and its downstream targets, p-c-JUN and p-ATF-2, in the cortex around the infarcts in the PCI group were significantly higher compared with those in the sham operation group ($P < 0.05$). In contrast, the cortex in the sNgR-Fc-treated group showed,

1
2 on average, reductions in the levels of p-JNK1, 2, p-c-JUN and p-ATF-2 to their basal levels
3
4 ($P < 0.05$). The levels of total JNK1, 2 were not different among the three groups ($P > 0.05$).
5
6 These results demonstrate that the cortical infarction injury activates the SAPK/JNK signal
7
8 pathway and that treatment with sNgR-Fc has the potential to decrease or prevent this
9
10 activation (Fig.3, Table 1).
11
12
13
14

15 **Discussion**

16
17
18 Watson et al reported a stroke model induced by a photochemical method in 1985 [12]. The
19
20 principle underlying this model was based on a photochemical reaction. Following the
21
22 injection of a potent photosensitive agent into rats, ischemic lesions were formed by
23
24 irradiating the left parietal convexities of the exposed skulls under a light with a specific
25
26 wavelength. Free radicals were released, damaging the endothelium of the cerebral vessels
27
28 and inducing platelet aggregation. Furthermore, this pathology causes thrombosis in cerebral
29
30 parenchymal vessels and results in irreversible hypoxic-ischemic brain damage (HIBD).
31
32 Because of the advantages of a stable location and infarction volume, a low mortality rate,
33
34 and a good replication rate, the stroke model is widely used in current studies of brain injury.
35
36
37 In this study, we successfully induced a cortical ischemic infarction model in rats in which
38
39 the BBB was also damaged. The primary pathological features of stroke were induced, and
40
41 the volumes of infarction were consistent. No infarction and no burn were observed in the
42
43 sham-group, indicating that the light stimulation alone did not induce the infarction and that it
44
45 acts as a good control.
46
47
48
49
50
51
52
53
54
55

56
57 Delayed neuron death (DND) is an important pathology of cerebral ischemia and
58
59 cerebral degenerative disease. Cell apoptosis was the primary DND pattern after an acute
60
61

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

HIBD, which aggravated the injury of sub-acute or chronic cerebral infarction [15, 16]. In our study, axonal pathologies were observed via the TEM at 7 days after PCI, including many edemas in the axoplasm of axons that have no medulla sheath, and thickening or shrinkage in the sheaths of the axons that have a medulla sheath. However, these conditions improved after sNgR-Fc treatment. The administration of the soluble NgR1 fusion protein (sNgR-Fc) effectively blocked the interaction of myelin molecules with NgR1 and promoted axon sprouting and functional recovery after spinal cord injuries[7–9], or dorsal root rhizotomy[10]. A previous study found that Nogo-A is involved in the secondary axonal degeneration of the thalamus with cerebral infarction in hypertensive rats [17] and after a focal ischemic stroke [18]. Anti-Nogo-A antibody improved behavioral outcome and corticospinal plasticity but did not decrease the infarct volume after experimental stroke [11]. In this study, sNgR-Fc did not cause any difference on infarct volume, but still provided protection of axons as observed in TEM.

Nogo-A, MAG and OMgp were considered to be the inhibitory factors of axonal regeneration in the CNS. NgR1 mediates their inhibitory effect via two co-receptors, p75 and Lingo-1, and transduces the signals via RhoA and its downstream pathways [19, 20]. In this study, the level of the GTP-RhoA protein in the model group was significantly higher than that of the sham-operation group. With the treatment of sNgR-Fc, the level of the GTP-RhoA protein was significantly decreased, suggesting that sNgR-Fc may promote axonal recovery by preventing the activation of RhoA after cerebral infarction.

The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway is a powerful signaling pathway under the stresses of ultraviolet light, radiation and inflammation [21–23]. In publications on neuronal apoptosis, some of the proteins in the

mitogen-activated protein kinases (MAPK) signaling pathways have been well-studied in recent years. The MAPK signaling pathway is a family of serine/threonine kinases that include three members: the extracellular signal-regulated protein kinases (ERK), JNK and p38 [24]. The JNK/SAPK and p38 are induced by cellular stress and some of the cytokines. The JNK protein can be activated by many stress stimulators, such as lipopolysaccharide (LPS), tumor necrosis factor- α (TNF- α), interleukin (IL)-1 or ultraviolet light. Activation of the JNK signaling pathway is related to cell apoptosis [24]. Following its activation, JNKs may phosphorylate specific sites of some of the transcription factors, such as ATF-2, SAP-1 and Elk-1, and increase the expression of genes, subsequently increasing the synthesis of proteins that may participate in the apoptosis pathway and cause cell death [25]. We found high levels of p-JNK, p-c-JUN and p-ATF-2 after stroke injury, indicating that cortical infarction activates the SAPK/JNK signal pathway and leads to the pathology of tissues and cells. The administration of sNgR-Fc decreased the activation of those proteins, suggesting that sNgR-Fc has the potential to prevent or decrease the activation of the SAPK/JNK signal pathway. We previously identified that sNgR-Fc binds to Nogo66, OMgp, and MAG [9] and inhibited the Nogo66-NgR interaction [6]. sNgR-Fc may protect axons by inhibiting the interaction of Nogo-A-NgR1 after stroke injury, decreasing the activation of RhoA and JNK. A schematic diagram illustrating the proposed mechanism for sNgR-Fc on axons in stroke is shown in Figure 4: In normal conditions, the cortex expresses low levels of Nogo-A and NgR1. However, cortical infarction under stroke injury increases the expression of Nogo-A and NgR1. Nogo-A activates RhoA and JNK signaling pathways via interacting with NgR1 and then results in pathological changes on axons. sNgR-Fc perturbs the interaction of Nogo-A and NgR1, decreases the activation of RhoA and JNK signaling pathways and

relieving the pathological changes of axons.

1
2 RhoA regulates the intracellular microfilament associated with cell proliferation through a
3
4 series of complex mechanisms [26]. Previous studies have observed that RhoA stimulates Jun
5
6 expression through the Rho-associated kinase (ROCK), which phosphorylates c-Jun and
7
8 ATF2 after binding to the c-Jun promoter [27]. In this study, we observed that changes in the
9
10 expression of p-JNK, p-c-Jun and p-ATF-2 were consistent with changes in the GTP-RhoA
11
12 level following both the cerebral infarction and the sNgR-Fc treatment. These findings
13
14 suggest that sNgR-Fc can relieve the axonal pathology partially by decreasing the activation
15
16 of the SAPK/JNK signal pathways.
17
18
19
20
21
22

23
24 In summary, pathological changes in axons were induced by the cerebral
25
26 hypoxia-ischemia for an extended period after the cortical infarction. This phenomenon may
27
28 be associated with the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. We
29
30 determined that an NgR1 antagonist, sNgR-Fc, alleviated axonal pathology changes and
31
32 prevented the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. Further studies
33
34 should be performed before this treatment is used in a clinical study.
35
36
37
38
39
40
41
42

43 **Acknowledgements**

44
45 This study was supported by funding from the NSFC (81272062, 81071030), Science
46
47 and Technology Foundation of Guangdong Province, China (2012B031800286 ,
48
49 2010B031600089) and the Fundamental Research Funds for the Central Universities
50
51 (09ykpy31). The funders had no role in the study design, data collection, analysis, decision to
52
53 publish or the preparation of the manuscript. Biogen Idec, Inc. provided the sNgR-Fc in the
54
55 study.
56
57
58
59
60
61
62
63
64
65

Disclosure of potential conflicts of interest

The authors indicate no potential conflicts of interest.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Bühnemann C, Scholz A, Bernreuther C, Malik CY, Braun H, Schachner M et al (2006)
Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. *Brain* 129:3238–3248
2. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA et al (2000)
Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. *Nature* 403:434–439
3. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E et al (2002)
Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. *Neuron* 35:283–290
4. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL et al (2002)
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. *Nature* 417:941–944
5. GrandPre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal regeneration. *Nature* 417:547–551
6. Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E (2009) Blockade of Nogo receptor ligands promotes functional regeneration of sensory axons after dorsal root crush. *J Neurosci* 29:6285–6295
7. Ji B, Li M, Budel S, Pepinsky RB, Walus L, Engber TM et al (2005) Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury. *Eur J Neurosci* 22:587–594
8. Lee JK, Kim JE, Sivula M, Strittmatter SM (2004) Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. *J Neurosci* 24:6209–6217

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
9. Li S, Liu BP, Budel S, Li M, Ji B, Walus L et al (2004) Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. *J Neurosci* 24:10511–10520
 10. MacDermid VE, McPhail LT, Tsang B, Rosenthal A, Davies A, Ramer MS (2004) A soluble Nogo receptor differentially affects plasticity of spinally projecting axons. *Eur J Neurosci* 20:2567–2579
 11. Wiessner C, Bareyre FM, Allegrini PR, Mir AK, Frentzel S, Zurini M, et al (2003) Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. *J Cereb Blood Flow Metab.* 23:154-65.
 12. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD (1985) Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol* 17:497-504
 13. Gao M, Zhu SY, Tan CB, Xu B, Zhang WC, Du GH (2010) Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats. *J Asian Nat Prod Res* 12:407–418
 14. Zheng YQ, Liu JX, Wang JN, Xu L (2007) Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. *Brain Res* 1138:86–94
 15. Culmsee C, Plesnila N (2006) Targeting Bid to prevent programmed cell death in neurons. *Biochem Soc Trans* 34:1334–1340
 16. Plesnila N, Zhu C, Culmsee C, Gröger M, Moskowitz MA, Blomgren K (2004) Nuclear

translocation of apoptosis-inducing factor after focal cerebral ischemia. *J Cereb Blood Flow Metab* 24:458–466

17. Wang F, Liang Z, Hou Q, Xing S, Ling L, He M et al (2007) Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. *Neurosci Lett* 417:255–260
18. Cheatwood JL, Emerick AJ, Schwab ME, Kartje GL (2008) Nogo-A expression after focal ischemic stroke in the adult rat. *Stroke* 39:2091–2098
19. Kubo T, Hata K, Yamaguchi A, Yamashita T (2007) Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. *Curr Pharm Des* 13:2493–2499
20. Kubo T, Yamashita T (2007) Rho-ROCK inhibitors for the treatment of CNS injury. *Recent Patents CNS Drug Discov* 2:173–179
21. Schwab TS, Madison BB, Grauman AR, Feldman EL (2005) Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. *Apoptosis* 10:831–840
22. Zhang HM, Yuan J, Cheung P, Luo H, Yanagawa B, Chau D et al (2003) Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication. *J Biol Chem* 278:33011–33019
23. Koh SH, Lee YB, Kim KS, Kim HJ, Kim M, Lee YJ et al (2005) Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. *Eur J Neurosci* 22:301–309
24. Yasuda S, Sugiura H, Tanaka H, Takigami S, Yamagata K (2011) p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. *Cent Nerv Syst Agents Med*

Chem. 11:45-59.

- 1
2 25. Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N et al (2007) The
3
4 mitogen-activated protein kinase p38 regulates activator protein 1 by direct
5
6 phosphorylation of c-Jun. *Int J Biochem Cell Biol* 39:2278–2288
7
8
- 9
10 26. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS (2004) The
11
12 small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. *Mol*
13
14 *Cell* 14:29–41
15
16
- 17
18 27. Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. *Curr Opin Cell Biol*
19
20
21 9:240–246
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure Legends

1 **Figure 1. The morphology and characteristics of the rat brain after a stroke induced by**
2 **photothrombotic cortical injury.** (a) Representative photographs of the coronal brain
3 sections stained with 2,3,5-triphenyltetrazolium chloride in rats, (b) sham-operated rats, (c)
4 and photothrombotic cortical injury (PCI) rats. White indicates the infarct area (arrow).
5
6
7
8
9

10
11
12 **Figure 2. The protective effect of sNgR-Fc on axon neurons under transmission electron**
13 **microscope after stroke injury.** Ultrastructural appearances of morphology of axons in
14 sham-operated, PBS and sNgR-Fc groups: (a) Normal unmyelinated axons in sham-operated
15 group; (b) Extensive edema, axon deformity, dilution of cytoplasmic matrices and axonal
16 fusion in stroke model; (c) Slight edema and dilution of cytoplasmic matrices with the
17 treatment of sNgR-Fc in stroke model; (d) Normal myelinated axons in sham-operated group;
18 (e) Thickening, shrinking or amyloidosis was more in stroke model; (f) Little demyelination
19 and no amyloidosis of the myelin sheath were found with the treatment of sNgR-Fc in stroke
20 model; (g) Normal synapses in the sham-operated group; (h) Widened and swollen synaptic
21 cleft in stroke model; (i) Approximately normal synapses with the treatment of sNgR-Fc in
22 stroke model. Arrows show the changes in axons.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Figure 3. The RhoA, SAPK/JNK signaling pathways after stroke injury and with the**
39 **treatment of sNgR-Fc under Western blotting.** The levels of p-JNK, p-c-JUN, p-ATF-2
40 and GTP-RhoA increased after stroke injury. Treatment with sNgR-Fc decreased the levels of
41 p-JNK, p-c-JUN, p-ATF-2 and GTP-RhoA to normal levels.
42
43
44
45
46
47

48 **Figure 4. The diagram of the signaling pathways involved in the sNgR-Fc on axons after**
49 **stroke injury.** In the normal condition, there is low level of Nogo-A and NgR1 in the cortex.
50 However, the expression of Nogo-A and NgR1 is increased under stroke injury. The increased
51 Nogo-A binds with NgR1 to activate the downstream pathways of RhoA and JNK, and then
52 results in axonal pathology. The treatment of sNgR-Fc inhibits the interaction of Nogo-A and
53 NgR1, decreases the activation of RhoA and JNK signaling pathways and then relieves
54 axonal pathology.
55
56
57
58
59
60
61
62
63
64
65

The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats

Running title: The neuroprotection of NgR1 antagonist on cortical axons

Hong Zhan^{1,6}, Shu-Jie Sun^{4,6}, Jie Cai¹, Ying-Qing Li¹, Chun-Lin Hu¹, Daniel H.S. Lee³, Kwok-Fai So^{2,5}, Xin Li¹

¹Department of Emergency, The First Affiliated Hospital, Sun Yat-sen University, 58 ZhongShan II, Guangzhou, Guangdong, 510080, China

²Department of Anatomy and The State Key Laboratory of Brain and Cognitive sciences, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China

³Roche R&D Center (China) Ltd. 720 Cai Lun Road, Building, Pudong, Shanghai 201203, China

⁴Emergency Department, East Hospital of TongJi University, 150 Jimo Road, Shanghai, People's Republic of China

⁵GHM Institute of CNS Regeneration, Jinan University, Guangzhou, China

⁶These authors contributed equally to this work.

Correspondence to:

Xin Li, MD

Associate Professor

Department of Emergency

The First Affiliated Hospital

Sun Yat-sen University

58 ZhongShan Road II, Guangzhou, Guangdong, 510080, China

Telephone: +86-20-28823350

Fax: +86-20-28823350.

E-mail: xlidoct@qq.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

1 We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of
2 cortical axons after cortical infarction in rats. The cortical infarction was induced by
3
4 cortical axons after cortical infarction in rats. The cortical infarction was induced by
5
6 photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was
7
8 injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using
9
10 histochemical and transmission-electron microscope techniques. The involved signaling
11
12 pathways, which include RhoA, JNK, c-JUN and ATF-2, were detected by Western blot.
13
14
15 Serious pathologies were found in the brains of the rats after injury, including edemas in the
16
17 axoplasms of axons that have no medulla sheath and a thickening or shrinkage in the sheath
18
19 of the axons that have medulla sheathes. However, these pathologies improved after sNgR-Fc
20
21 treatment. The levels of GTP-RhoA, p-JNK, p-c-JUN and p-ATF-2 in the PCI group were
22
23 increased when compared with their levels in the sham-operation group ($P < 0.05$), and
24
25 animals receiving the sNgR-Fc treatment showed lower expression levels of these proteins
26
27 when compared with the sham-operation group ($P < 0.05$). Our results suggest that sNgR-Fc
28
29 can alleviate the pathological changes of axons following cortical infarction via decreasing
30
31 the activation of RhoA/JNK signaling pathways.
32
33
34
35
36
37
38
39
40
41
42

43 **Key words:** Nogo-66 receptor; Axon; Cortical infarction; Regeneration; Signal pathway
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

1 A brain infarction (also known as an ischemic stroke) is caused by the blockage of a cerebral
2 artery by a blood clot, which results in the following effects: a critical reduction in blood flow,
3
4 ischemia, anoxia, and, finally, ischemic necrosis or encephalomalacia in the brain. This
5
6 condition is characterized clinically by high morbidity, high mortality, high disability rate,
7
8 high recurrence rates, and it is difficult to treat. Because our population is aging, stroke is
9
10 becoming a more serious threat and an urgent medical problem. Previous studies have shown
11
12 that the central nerve system cannot regenerate after injury, as a result of factors that include
13
14 the insufficiency of neural progenitor cells (NPCs) and a microenvironment that inhibits the
15
16 regeneration of neurons [1]. Recent studies have demonstrated that the inhibition of axon
17
18 regeneration after injuries to the central nervous system (CNS) were associated with several
19
20 CNS myelin proteins, including Nogo-A, myelin-associated glycoprotein (MAG), and
21
22 oligodendrocyte myelin glycoprotein (OMgp). These three proteins bind to the Nogo-66
23
24 receptor (NgR1), which then leads to the downstream activation of RhoA (Ras homolog gene
25
26 family, member A) via two transmembrane proteins, LINGO-1 and p75; these proteins inhibit
27
28 the activity in neurons and their axons [2–4]. Jun N-terminal kinases (JNKs) are intracellular
29
30 molecules related to stress stimuli. The activation of these molecules mediates many types of
31
32 injury-induced apoptosis and plays a role in the regeneration of axons. However, the role of
33
34 the JNK-signaling pathway in the presence of a brain infarction is still unclear. The
35
36 administration of sNgR-Fc, a recombinant rat soluble NgR-Fc fusion protein [5], has been
37
38 found to block the interaction of myelin proteins with NgR1 effectively and to promote the
39
40 regeneration of axons in rodent models of CNS injuries such as spinal cord injury [6–10]. A
41
42 previous study has shown that anti-Nogo-A antibody promoted the behavioral outcome and
43
44 corticospinal plasticity in a rat stroke model [11]. In this study, we established a stroke model
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 in rats and observed the effects of sNgR-Fc on the axonal pathology and the involved
3 RhoA/JNK signaling pathways after cortical infarction.
4
5
6

7 **Experimental Procedure**

8 **Animals**

9
10 The animal experiments were approved by the Committee for the Use of Live Animals in
11 Teaching and Research at the Sun Yat-sen University. All of the experiments were performed
12 in a fully randomized and blinded fashion.
13
14
15
16
17
18
19
20

21 **Photothrombotic cortical injury**

22 **Photothrombotic ischemia was induced in the rat parietal cortex using previously described**
23 **methods [9,11,12] with the modifications as outlined below.** Twenty seven male SD rats
24 weighing 250 g were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and
25 xylazine (8 mg/kg). Dilute Rose-Bengal in saline (40 mg/kg body weight) was infused into
26 the femoral vein. The portion of the skull exposed at 3 mm posteriorly to the bregma and 3
27 mm laterally from the midline was illuminated with a cold, white light beam (Volpi Intralux
28 6000, 150 W; Volpi AG, Schlieven, Switzerland) for 8 min at maximum output via a
29 fiber-optic bundle with a 10 mm aperture. The animals were randomly grouped into
30 sham-operation (operation + Rose-Bengal), PBS (operation + Rose-Bengal + PBS), or
31 sNgR-Fc (operation + Rose-Bengal + sNgR-Fc) groups ($n = 9$ for each group). A solution of
32 sNgR-Fc (400 μ g/kg body weight) in 10 μ l PBS or equivalent PBS was only once injected
33 into the ipsilateral ventricle using a 26-gauge sterile microsyringe 24 h after photothrombotic
34 cortical injury [11]. The site of injection was at 1 mm posteriorly to the bregma and 1.5 mm
35 laterally from the midline, and the depth of injection was about 3.5~4.0 mm. For each group,
36 the whole cerebrum of 3 animals was collected 24 h after injury for tissue staining. The
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 ipsilateral cortex of peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm
3 laterally from the midline of rats was collected at 27 d after injury for electron microscopy
4 examination ($n = 3$ for each group) and for Western blotting ($n = 3$ for each group).
5
6
7
8
9

10 **Triphenyltetrazolium chloride staining**

11
12 To evaluate the extent of cortical infarction, we used 2, 3, 5-Triphenyltetrazolium chloride
13 (TTC) to assess cerebral injury. At 24 h after PCI, the animals were sacrificed using an
14 overdose of pentobarbital sodium (150 mg/kg, Alcon-Couvreur, Rijksweg, Puurs, Belgium).
15
16 The brains were removed immediately and then were chilled at $-30\text{ }^{\circ}\text{C}$ for 4 min to slightly
17 freeze the tissue. Two-mm coronal sections from the olfactory bulb to the cerebellum were
18 prepared, stained with 1.5% TTC (Genetime) at $37\text{ }^{\circ}\text{C}$ for 30 min, and fixed in 10% buffered
19 formalin solution.
20
21
22
23
24
25
26
27
28
29
30

31 **Transmission electron microscopy**

32
33 Seven days after PCI, the peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm
34 laterally from the midline on the injury side was removed and immediately cut into 0.5 cm^3
35 cubes at $0\text{ }^{\circ}\text{C}$, fixed with 4% paraformaldehyde for 4 h, and washed with PBS. Then, the
36 tissue was fixed with 2% osmic acid for 2 h, washed with pure water, dehydrated with a
37 mixture of ethanol, propylene oxide, and resin, embedded in pure resin, and ultramicrocut
38 and stained with uranyl acetate and lead citrate [13, 14]. The sections were observed under an
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

54 **Western blotting**

56
57 The cortex from the injury side was collected at 7 days after injury and homogenized in a
58 lysis buffer (in mM: Tris, 10, pH 7.4; NaCl, 150; EDTA, 1; EGTA, 1; 10% protease inhibitor,
59 1% phosphatase inhibitor), and incubated on ice for 30 min. The protein lysate was then
60
61
62
63
64
65

1 centrifuged at 13,500 rpm for 30 min at 4 °C. The supernatant was aliquoted and stored at
2 -80 °C until its use. The supernatant was measured for its protein concentration using a
3
4 Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 40 µg aliquot of protein
5
6 from each sample was subjected to 5–12% SDS–polyacrylamide gel electrophoresis and
7
8 transferred onto a PVDF membrane. Each membrane was blocked with 5% non-fat milk and
9
10 2% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h
11
12 at room temperature and then probed with rabbit anti-p-JNK (Cell Signaling Technology,
13
14 MA, USA), anti-p-c-JUN (Cell Signaling Technology), p-ATF-2 (Cell Signaling
15
16 Technology), total-JNK (Cell Signaling Technology) and total-RhoA antibodies at 4 °C
17
18 overnight. As a gel loading control, β-actin was used. After washing, the membranes were
19
20 incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:2000;
21
22 DakoCytomation, Denmark). Its immunoreactivity was visualized using the Amersham
23
24 enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA). The protein loading
25
26 was controlled using the goat antibody against β-actin (C-11; Santa Cruz Biotechnology).
27
28 The quantification of the results was performed by densitometry, and the results were
29
30 analyzed as total integrated densitometric values (arbitrary units). The protein GTP-RhoA
31
32 was pulled down using a RhoA activation assay kit, according to the manufacturer's
33
34 instruction (Cytoskeleton, Denver, CO, USA) and assayed by Western blotting using an
35
36 antibody against RhoA (Cytoskeleton). All experiments for Western blotting were performed
37
38 with 3 animals in each group, and the samples were run on the gels as individual animals.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Data and statistical analysis**

55 The values are presented as the mean ± SD. The statistical analyses was performed
56
57 using Student's t-test for comparisons between two groups or the one-way analysis of
58
59 variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) for comparisons of
60
61
62
63
64
65

more than two groups. The data were analyzed statistically with the software SPSS 12.0. The significance level was set at $P < 0.05$.

Results

Measurement of brain infarct volume and identification of blood brain barrier integrity

After TTC staining, the rats in the sham group did not appear to have any infarctions (Fig. 1b). However, the right parietal lobes of the rats 24 h after PCI presented pale infarctions that were bowl-shaped, with the bottom pointing to the lateral ventricle; these infarctions affected the entire cortex. The total infarct volumes were $297.1 \pm 23.4 \mu\text{l}$ in the PBS group and $285.4 \pm 19.7 \mu\text{l}$ for the sNgR-Fc group respectively before the treatment. The locations of the infarctions were stable, and the infarctions showed similar volumes to those in the rats (Fig. 1).

Pathological changes of axons

The morphology of ischemic penumbra on the injury side was evaluated using TEM at 7 days after PCI. Compared with the normal axons observed in the sham group (Fig. 2a), more serious pathologies were observed in the PCI group (Fig. 2b). For the axons without a medulla sheath, many edemas, dilutions of cytoplasmic matrices, and axonal fusions or dissolutions were found. Occasionally, we observed that oligodendrocytes appeared to “swallow” the axons (Fig. 2b). For axons with a medulla sheath, compared with the sham group, thickening or shrinking was more in the axoplasm of the fibers, and amyloidosis and swollen axons were observed at a higher rate. In addition, the axolemma were found to be separated from the inner layers of the myelin (Fig. 2e). In addition, there were only minor pathological changes, including slight nuclear edemas with complete nucleoli, slightly swollen mitochondria, and slightly widened endoplasmic reticula with complete ribosomes

1 and Golgi bodies. In unmyelinated axons, there were some axonal edemas, axonal
2 deformities, and dilutions of cytoplasmic matrices; in addition, there were no axonal fusions
3
4 or cytophagic effects of oligodendrocytes (Fig. 2c). In myelinated axons, the morphology of
5
6 axons was almost normal. There was little demyelination and no amyloidosis of the myelin
7
8 sheath was found (Fig. 2f). Compared with normal synapses (Fig. 2g), the synaptic cleft
9
10 widened, and there was edema in the PBS group (Fig. 2h). However, no clear edema or
11
12 widening of the synaptic cleft was observed in the group that received the sNgR-Fc treatment
13
14
15
16
17
18 (Fig. 2i).

21 **sNgR-Fc inhibited RhoA signal pathway**

22
23 The level of GTP-RhoA in the PBS group was significantly higher than that in the
24
25 sham-operation group ($P < 0.05$). After treatment with sNgR-Fc, the level of GTP-RhoA was
26
27 significantly decreased. Moreover, the level of Total-RhoA was not different among the three
28
29 groups (Fig.3, Table 1). **These data indicate that sNgR-Fc could decrease the activation of**
30
31 **RhoA.**

37 **sNgR-Fc inhibit the activation of SAPK/JNK signal pathway**

38
39 The levels of p-JNK1, 2 and its downstream targets, p-c-JUN and p-ATF-2, in the cortex
40
41 around the infarcts in the PCI group were significantly higher compared with those in the
42
43 sham operation group ($P < 0.05$). In contrast, the cortex in the sNgR-Fc-treated group showed,
44
45 on average, reductions in the levels of p-JNK1, 2, p-c-JUN and p-ATF-2 to their basal levels
46
47
48
49
50
51 ($P < 0.05$). The levels of total JNK1, 2 were not different among the three groups ($P > 0.05$).
52
53
54 These results demonstrate that the cortical infarction injury activates the SAPK/JNK signal
55
56 pathway and that treatment with sNgR-Fc has the potential to decrease or prevent this
57
58
59
60
61
62
63
64
65 activation (Fig.3, Table 1).

Discussion

1 Watson et al reported a stroke model induced by a photochemical method in 1985 [12]. The
2 principle underlying this model was based on a photochemical reaction. Following the
3
4 injection of a potent photosensitive agent into rats, ischemic lesions were formed by
5
6 irradiating the left parietal convexities of the exposed skulls under a light with a specific
7
8 wavelength. Free radicals were released, damaging the endothelium of the cerebral vessels
9
10 and inducing platelet aggregation. Furthermore, this pathology causes thrombosis in cerebral
11
12 parenchymal vessels and results in irreversible hypoxic-ischemic brain damage (HIBD).
13
14 Because of the advantages of a stable location and infarction volume, a low mortality rate,
15
16 and a good replication rate, the stroke model is widely used in current studies of brain injury.
17
18 In this study, we successfully induced a cortical ischemic infarction model in rats in which
19
20 the BBB was also damaged. The primary pathological features of stroke were induced, and
21
22 the volumes of infarction were consistent. No infarction and no burn were observed in the
23
24 sham-group, indicating that the light stimulation alone did not induce the infarction and that it
25
26 acts as a good control.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Delayed neuron death (DND) is an important pathology of cerebral ischemia and
41
42 cerebral degenerative disease. Cell apoptosis was the primary DND pattern after an acute
43
44 HIBD, which aggravated the injury of sub-acute or chronic cerebral infarction [15, 16]. In our
45
46 study, axonal pathologies were observed via the TEM at 7 days after PCI, including many
47
48 edemas in the axoplasm of axons that have no medulla sheath, and thickening or shrinkage in
49
50 the sheaths of the axons that have a medulla sheath. However, these conditions improved
51
52 after sNgR-Fc treatment. The administration of the soluble NgR1 fusion protein (sNgR-Fc)
53
54 effectively blocked the interaction of myelin molecules with NgR1 and promoted axon
55
56 sprouting and functional recovery after spinal cord injuries[7–9], or dorsal root rhizotomy[10].
57
58
59
60
61
62
63
64
65

1
2 A previous study found that Nogo-A is involved in the secondary axonal degeneration of the
3 thalamus with cerebral infarction in hypertensive rats [17] and after a focal ischemic stroke
4 [18]. Anti-Nogo-A antibody improved behavioral outcome and corticospinal plasticity but
5 did not decrease the infarct volume after experimental stroke [11]. In this study, sNgR-Fc did
6 not cause any difference on infarct volume, but still provided protection of axons as observed
7 in TEM.
8
9

10
11 Nogo-A, MAG and OMgp were considered to be the inhibitory factors of axonal
12 regeneration in the CNS. NgR1 mediates their inhibitory effect via two co-receptors, p75 and
13 Lingo-1, and transduces the signals via RhoA and its downstream pathways [19, 20]. In this
14 study, the level of the GTP-RhoA protein in the model group was significantly higher than
15 that of the sham-operation group. With the treatment of sNgR-Fc, the level of the GTP-RhoA
16 protein was significantly decreased, suggesting that sNgR-Fc may promote axonal recovery
17 by preventing the activation of RhoA after cerebral infarction.
18
19

20
21 The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling
22 pathway is a powerful signaling pathway under the stresses of ultraviolet light, radiation and
23 inflammation [21–23]. In publications on neuronal apoptosis, some of the proteins in the
24 mitogen-activated protein kinases (MAPK) signaling pathways have been well-studied in
25 recent years. The MAPK signaling pathway is a family of serine/threonine kinases that
26 include three members: the extracellular signal-regulated protein kinases (ERK), JNK and
27 p38 [24]. The JNK/SAPK and p38 are induced by cellular stress and some of the cytokines.
28
29 The JNK protein can be activated by many stress stimulators, such as lipopolysaccharide
30 (LPS), tumor necrosis factor- α (TNF- α), interleukin (IL)-1 or ultraviolet light. Activation of
31 the JNK signaling pathway is related to cell apoptosis [24]. Following its activation, JNKs
32 may phosphorylate specific sites of some of the transcription factors, such as ATF-2, SAP-1
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 and Elk-1, and increase the expression of genes, subsequently increasing the synthesis of
2 proteins that may participate in the apoptosis pathway and cause cell death [25]. We found
3
4 high levels of p-JNK, p-c-JUN and p-ATF-2 after stroke injury, indicating that cortical
5
6 infarction activates the SAPK/JNK signal pathway and leads to the pathology of tissues and
7
8 cells. The administration of sNgR-Fc decreased the activation of those proteins, suggesting
9
10 that sNgR-Fc has the potential to prevent or decrease the activation of the SAPK/JNK signal
11
12 pathway. We previously identified that sNgR-Fc binds to Nogo66, OMgp, and MAG [9] and
13
14 inhibited the Nogo66-NgR interaction [6]. sNgR-Fc may protect axons by inhibiting the
15
16 interaction of Nogo-A-NgR1 after stroke injury, decreasing the activation of RhoA and JNK.
17
18 A schematic diagram illustrating the proposed mechanism for sNgR-Fc on axons in stroke is
19
20 shown in Figure 4: In normal conditions, the cortex expresses low levels of Nogo-A and
21
22 NgR1. However, cortical infarction under stroke injury increases the expression of Nogo-A
23
24 and NgR1. Nogo-A activates RhoA and JNK signaling pathways via interacting with NgR1
25
26 and then results in pathological changes on axons. sNgR-Fc perturbs the interaction of
27
28 Nogo-A and NgR1, decreases the activation of RhoA and JNK signaling pathways and
29
30 relieving the pathological changes of axons.
31
32
33
34
35
36
37
38
39
40
41
42

43 RhoA regulates the intracellular microfilament associated with cell proliferation through a
44
45 series of complex mechanisms [26]. Previous studies have observed that RhoA stimulates Jun
46
47 expression through the Rho-associated kinase (ROCK), which phosphorylates c-Jun and
48
49 ATF2 after binding to the c-Jun promoter [27]. In this study, we observed that changes in the
50
51 expression of p-JNK, p-c-Jun and p-ATF-2 were consistent with changes in the GTP-RhoA
52
53 level following both the cerebral infarction and the sNgR-Fc treatment. These findings
54
55 suggest that sNgR-Fc can relieve the axonal pathology partially by decreasing the activation
56
57 of the SAPK/JNK signal pathways.
58
59
60
61
62
63
64
65

1
2 In summary, pathological changes in axons were induced by the cerebral
3 hypoxia-ischemia for an extended period after the cortical infarction. This phenomenon may
4 be associated with the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. We
5 determined that an NgR1 antagonist, sNgR-Fc, alleviated axonal pathology changes and
6 prevented the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. Further studies
7 should be performed before this treatment is used in a clinical study.
8
9
10
11
12
13
14
15
16
17

18 **Acknowledgements**

19
20
21 This study was supported by funding from the NSFC (81272062, 81071030), Science
22 and Technology Foundation of Guangdong Province, China (2012B031800286 ,
23 2010B031600089) and the Fundamental Research Funds for the Central Universities
24 (09ykpy31). The funders had no role in the study design, data collection, analysis, decision to
25 publish or the preparation of the manuscript. Biogen Idec, Inc. provided the sNgR-Fc in the
26 study.
27
28
29
30
31
32
33
34
35
36

37 **Disclosure of potential conflicts of interest**

38
39
40 The authors indicate no potential conflicts of interest.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Bühnemann C, Scholz A, Bernreuther C, Malik CY, Braun H, Schachner M et al (2006) Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. *Brain* 129:3238–3248
2. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA et al (2000) Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. *Nature* 403:434–439
3. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E et al (2002) Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. *Neuron* 35:283–290
4. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL et al (2002) Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. *Nature* 417:941–944
5. GrandPre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal regeneration. *Nature* 417:547–551
6. Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E (2009) Blockade of Nogo receptor ligands promotes functional regeneration of sensory axons after dorsal root crush. *J Neurosci* 29:6285–6295
7. Ji B, Li M, Budel S, Pepinsky RB, Walus L, Engber TM et al (2005) Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury. *Eur J Neurosci* 22:587–594
8. Lee JK, Kim JE, Sivula M, Strittmatter SM (2004) Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. *J Neurosci* 24:6209–6217
9. Li S, Liu BP, Budel S, Li M, Ji B, Walus L et al (2004) Blockade of Nogo-66,

myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. *J Neurosci* 24:10511–10520

10. MacDermid VE, McPhail LT, Tsang B, Rosenthal A, Davies A, Ramer MS (2004) A soluble Nogo receptor differentially affects plasticity of spinally projecting axons. *Eur J Neurosci* 20:2567–2579
11. Wiessner C, Bareyre FM, Allegrini PR, Mir AK, Frentzel S, Zurini M, et al (2003) Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. *J Cereb Blood Flow Metab.* 23:154-65.
12. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD (1985) Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol* 17:497-504
13. Gao M, Zhu SY, Tan CB, Xu B, Zhang WC, Du GH (2010) Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats. *J Asian Nat Prod Res* 12:407–418
14. Zheng YQ, Liu JX, Wang JN, Xu L (2007) Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. *Brain Res* 1138:86–94
15. Culmsee C, Plesnila N (2006) Targeting Bid to prevent programmed cell death in neurons. *Biochem Soc Trans* 34:1334–1340
16. Plesnila N, Zhu C, Culmsee C, Gröger M, Moskowitz MA, Blomgren K (2004) Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia. *J Cereb Blood Flow Metab* 24:458–466

17. Wang F, Liang Z, Hou Q, Xing S, Ling L, He M et al (2007) Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. *Neurosci Lett* 417:255–260
18. Cheatwood JL, Emerick AJ, Schwab ME, Kartje GL (2008) Nogo-A expression after focal ischemic stroke in the adult rat. *Stroke* 39:2091–2098
19. Kubo T, Hata K, Yamaguchi A, Yamashita T (2007) Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. *Curr Pharm Des* 13:2493–2499
20. Kubo T, Yamashita T (2007) Rho-ROCK inhibitors for the treatment of CNS injury. *Recent Patents CNS Drug Discov* 2:173–179
21. Schwab TS, Madison BB, Grauman AR, Feldman EL (2005) Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. *Apoptosis* 10:831–840
22. Zhang HM, Yuan J, Cheung P, Luo H, Yanagawa B, Chau D et al (2003) Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication. *J Biol Chem* 278:33011–33019
23. Koh SH, Lee YB, Kim KS, Kim HJ, Kim M, Lee YJ et al (2005) Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. *Eur J Neurosci* 22:301–309
24. Yasuda S, Sugiura H, Tanaka H, Takigami S, Yamagata K (2011) p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. *Cent Nerv Syst Agents Med Chem*. 11:45-59.
25. Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N et al (2007) The mitogen-activated protein kinase p38 regulates activator protein 1 by direct

phosphorylation of c-Jun. *Int J Biochem Cell Biol* 39:2278–2288

- 1
2 26. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS (2004) The
3
4 small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. *Mol*
5
6
7 *Cell* 14:29–41
8
9
- 10 27. Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. *Curr Opin Cell Biol*
11
12 9:240–246
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure Legends

1 **Figure 1. The morphology and characteristics of the rat brain after a stroke induced by**
2 **photothrombotic cortical injury.** (a) Representative photographs of the coronal brain
3 sections stained with 2,3,5-triphenyltetrazolium chloride in rats, (b) sham-operated rats, (c)
4 and photothrombotic cortical injury (PCI) rats. White indicates the infarct area (arrow).
5
6
7
8
9

10
11
12 **Figure 2. The protective effect of sNgR-Fc on axon neurons under transmission electron**
13 **microscope after stroke injury.** Ultrastructural appearances of morphology of axons in
14 sham-operated, PBS and sNgR-Fc groups: (a) Normal unmyelinated axons in sham-operated
15 group; (b) Extensive edema, axon deformity, dilution of cytoplasmic matrices and axonal
16 fusion in stroke model; (c) Slight edema and dilution of cytoplasmic matrices with the
17 treatment of sNgR-Fc in stroke model; (d) Normal myelinated axons in sham-operated group;
18 (e) Thickening, shrinking or amyloidosis was more in stroke model; (f) Little demyelination
19 and no amyloidosis of the myelin sheath were found with the treatment of sNgR-Fc in stroke
20 model; (g) Normal synapses in the sham-operated group; (h) Widened and swollen synaptic
21 cleft in stroke model; (i) Approximately normal synapses with the treatment of sNgR-Fc in
22 stroke model. Arrows show the changes in axons.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Figure 3. The RhoA, SAPK/JNK signaling pathways after stroke injury and with the**
39 **treatment of sNgR-Fc under Western blotting.** The levels of p-JNK, p-c-JUN, p-ATF-2
40 and GTP-RhoA increased after stroke injury. Treatment with sNgR-Fc decreased the levels of
41 p-JNK, p-c-JUN, p-ATF-2 and GTP-RhoA to normal levels.
42
43
44
45
46
47

48 **Figure 4. The diagram of the signaling pathways involved in the sNgR-Fc on axons after**
49 **stroke injury.** In the normal condition, there is low level of Nogo-A and NgR1 in the cortex.
50 However, the expression of Nogo-A and NgR1 is increased under stroke injury. The increased
51 Nogo-A binds with NgR1 to activate the downstream pathways of RhoA and JNK, and then
52 results in axonal pathology. The treatment of sNgR-Fc inhibits the interaction of Nogo-A and
53 NgR1, decreases the activation of RhoA and JNK signaling pathways and then relieves
54 axonal pathology.
55
56
57
58
59
60
61
62
63
64
65





Figure 1




Figure 2




Figure 3




Figure 4

Table 1 The density of the key proteins of RhoA and SAPK/JNK signal pathway

	Sham-operated	PBS	sNgR.Fc
GTP-RhoA	1.0±0.14	1.73±0.16 [▲]	1.10±0.13 ^{▲■}
Total-RhoA	1.0±0.09	0.97±0.11	0.98±0.10
p-ATF-2	1.0±0.12	2.19±0.24 [▲]	1.53±0.22 ^{▲■}
p-c-JUN	1.0±0.062	1.39±0.139 [▲]	1.12±0.058 ^{▲■}
p-JNK1	1.0±0.29	2.24±0.27 [▲]	1.30±0.31 ^{▲■}
p-JNK2	1.0±0.14	1.73±0.12 [▲]	1.02±0.15 ^{▲■}
Total-JNK1	1.0±0.08	1.01±0.09	1.01±0.08
Total-JNK2	1±0.09	0.99±0.11	0.98±0.12

[▲]P<0.05 vs Sham-operated group; [■]P<0.05 vs PBS group, Mean ±SD, n = 3)